EMERYVILLE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- NovaCal Pharmaceuticals Inc. (“NovaCal”) announced today that it has signed a collaboration and license agreement with an affiliate of Alcon, Inc. (NYSE: ACL - News), the world’s leading eye care company, to research, develop and commercialize NovaCal’s novel Aganocide(TM) compounds to treat infections of the eye, ear and sinus, including those associated with persistent bacterial biofilms.
